Beckman Coulter

Under the agreement, Beckman Coulter will sell and distribute Genedrive's high-throughput SARS-CoV-2 test in the US and Europe.

The company's life sciences revenues grew 76 percent, while diagnostics revenues increased 24 percent.

The revenue increase was driven by significant growth in the conglomerate's life sciences segment.

The commercial labs will also receive testing equipment from Beckman Coulter Life Sciences and Thermo Fisher Scientific including RT-PCR instrumentation.

The companies are validating the Genedrive 96 Sars-CoV-2 kit using saliva samples extracted with Beckman Coulter's RNAdvance viral extraction chemistry

For the three months ended July 3, the Washington DC-based conglomerate recorded $5.30 billion in total sales compared to $4.44 billion in the year-ago period.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.